Aktienanalyse zu vTv Therapeutics Inc (VTVT)VTVTvTv Therapeutics Inc

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, vTv Therapeutics Inc is not a strong buy. The stock is priced at $24.15, significantly below its 52-week high of $44.00, indicating a potential for recovery. However, the RSI is at a low 22.136, suggesting the stock is oversold, which could indicate a buying opportunity. The upcoming earnings report on November 5, 2026, is expected to show an EPS of -1.07, which may further impact investor sentiment negatively. The main risk is the company's recent earnings miss, with a reported EPS of -1.05 compared to an estimate of -0.75, raising concerns about profitability and cash flow management.

4 analysts cover VTVT: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 51.33.